Share Price, page-4740

.
As a suggested question for Jon Pilcher tomorrow in Melbourne.... if someone present could please ask him what he thinks

"Would it be a good idea to restructure Neuren by creating a separate listed company to hold the NNZ2591 assets?"

The reason being that if Big Pharma comes after Trofinitide we will still be left with the full value of NNZ2591 ....
.
Neuren Pharma Limited (our existing company) …. Retains cash+ income stream + Trofinitide North America (Arcadia) + Trofinetide for ROW (rest of world). Still in the ASX top 200..·
.
Son of Neuren (SON) (to be created) ,,, NNZ 2591 for 4x indications + slab of shares in Neuren Pharma Limited.·

Could also create:--

Daughter of Neuren (DON) … NNZ 2591 for everything else including Trofinetide for Traumatic Brain Injury and another slab of shares in Neuren Pharma Limited
.
Suggested mechanism is that all shareholders at date be each issued with· 2x shares in Neuren Pharma + 1 share in Son-of-Neuren (SON) + options sweetener + 1 share in Daughter-of-Neuren (DON) + options sweetener .
.
The existing cash and future cash flow from Trofinitide is able to flow from Neuren Pharma Limited into SON and DON via dividends and/or share placements.
.
This way the shareholders achieve maximum value for any and all parts. It could be also argued that smaller shareholders benefit from the options sweetener and thus a payback against being "financially flensed" via the market manipulation by our biggest institutional shareholder a few months ago.
.

.